Latest News
DKSH partners with life science innovator Nicoya in Asia

Source: Press by DKSH

DKSH has signed a strategic agreement with Nicoya to promote their surface plasmon resonance (SPR) instruments in key Asian markets. This partnership is in line with the strategic focus of DKSH Business Unit Technology to solidify its position as a leading integrated solutions provider for the scientific Instrumentation market.

DKSH Business Unit Technology has entered into an exclusive partnership with Nicoya, an innovative manufacturer of SPR instruments, headquartered in Kitchener, Canada. DKSH will provide marketing, sales and after-sales services support in selected markets across Asia, including Indonesia, Malaysia, Philippines, Taiwan, Thailand, Singapore and Vietnam.

Nicoya has developed Alto, the world’s first digital high-throughput benchtop SPR instrument. It is capable of accelerating drug discovery using a fraction of sample volume traditionally required for biomolecular interaction analyses. Alto helps biotechnology and pharmaceutical companies go to market faster with increased efficiency and success early in their product pipelines.

“DKSH has unique regional coverage, in-depth knowledge and a broad network of laboratories doing research on biomolecules and nanoparticles. We are convinced that DKSH is the right partner to help us excel in the demanding scientific application for SPR, expand our coverage and meet our aggressive growth goals,” said David Panzarella, Chief Commercial Officer, Nicoya.

Marco Farina, Senior Director, Business Development, Scientific Instrumentation, DKSH Business Unit Technology, commented: “The partnership with Nicoya helps strengthen our leadership in the characterization of biomolecular interactions and expand our life sciences footprint. We are confident to grow the market with Nicoya, leveraging our expertise through our Center of Excellence, good sales coverage, strong application support and world-class after-sales services.”

Information appearing on this website (images and texts, unless otherwise indicated) is the property of IBMI. To use or share, please indicate the source.
© 2024 Institute for Biotechnology and Medicine Industry (IBMI) All rights reserved.
Address:16F.-1, No.3, Park St., Nangang Dist., Taipei City 115, Taiwan (R.O.C.) Contact Number:(02)2655-8168 Fax:(02)2655-7978